Publication | Open Access
Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study
589
Citations
19
References
2016
Year
Phase 1BMedicineImmunologyPharmacologyImmune Checkpoint InhibitorAnti-cancer AgentCancer TreatmentAntitumour ActivityOncologyLung Cancer
| Year | Citations | |
|---|---|---|
Page 1
Page 1